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Abstract
Background: Senkyunolide I (SEI) is one of the most important bioactive phthalides of Ligusticum chuanxiong Hort.
(Umbelliferae), a Traditional Chinese Medicine. Our previous studies suggested that it might be developed as
a potential treatment for migraine.
Methods: In this paper, we aimed to isolate and characterize the main metabolites of SEI after gavage feeding in rats.
Their structures were identified precisely on the basis of nuclear magnetic resonance (NMR) spectroscopy and UPLC/Q-
TOF-MS spectrometry. We also established the main metabolic pathways of SEI in rats.
Results: Four metabolites (M1-M4) were isolated, for the first time, from bile samples of rats by preparative
high-performance liquid chromatography. Their structures were determined as SEI-6S-O-β-D-glucuronide (M1),
SEI-7S-O-β-D-glucuronide (M2), SEI-7S-S-glutathione (M3) and SEI-7R-S-glutathione (M4) on the basis of the
molecular mass of the analytes, using ultra performance liquid chromatography/quadrupole-time-of-flight mass
spectrometry and 1D and 2D NMR.
Conclusions: The results demonstrated that glucuronide and glutathione conjugation were the major pathways of
SEI metabolism in vivo, and the configuration at the 7th-position could be inverted during glutathione conjugation.
Keywords: Senkyunolide I, Metabolites, UPLC/Q-TOF-MS, NMR, In vivo
Background
Ligusticum chuanxiong Hort. (Umbelliferae) is a trad-
itional Chinese herbal medicine that has been used to
treat cardio- and cerebro-vascular disorders, such as
angina pectoris, stroke and migraine, in China for
thousands of years [1]. The chemistry and pharmaco-
logical effects of chuanxiong have been well documented.
Phthalides have been reported as the primary bioactive
constituents in this herb. Various pharmacological
activities of the main phthalides, such as ligustilide
and senkyunolide A, have been revealed, and their
contributions to the beneficial effects of the herb are
supported by in vivo and in vitro studies [2–5].
Senkyunolide I (SEI, Fig. 1), a representative metabolite
of ligustilide in vivo and in vitro [6, 7], is one of the most
important bioactive constituents of chuanxiong [6, 8–11].
Several studies have demonstrated that SEI could decrease
hydrogen peroxide (H2O2)-induced oxidative damage
in cultured human liver HepG2 cells [7] and PC12
cells [12]. SEI could also decrease the morphological
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damage to red blood cells induced by concanavalin A
[13]. Our previous study demonstrated that SEI could
treat migraines, although the mechanism is unclear
[14]. In addition, SEI is more stably in vitro, and has
higher solubility [15, 16] and higher oral bioavailability
[17, 18] compared with ligustilide and senkyunolide A.
These properties of SEI suggest that it has a better
potential as a new drug than ligustilide and senkyu-
nolide A.
Generally, drug metabolism has a significant impact
on the safety and efficacy of a drug and is commonly
investigated at early stage of new drugs development.
The identification of the drug’s metabolites is indispens-
able in this process [19]. Liquid chromatography (LC)
coupled with tandem mass spectrometry has become a
powerful tool to study drug metabolism because of its
superior sensitivity and specificity [20, 21]. Quadrupole-
time-of-flight mass spectrometry (Q/TOF-MS) is very
useful in the characterization of drug metabolites
because the technique provides accurate masses of ions
and reveals valuable structural information [22]. In our
previous study [23], 18 metabolites were characterized
on the basis of ultra performance liquid chromatog-
raphy/Q/TOF-MS (UPLC/Q-TOF-MS) analysis. How-
ever, because there are two chiral carbons (6-C and
7-C) in the molecular structure of SEI, the chemical
structures of SEI conjugates present in vivo have not
been fully characterized using Q/TOF-MS. To
confirm further the structures of the main metabo-
lites, and to obtain the pharmacological and toxico-
logical information on them, it is essential to obtain
adequate reference standards. Therefore, as part of
our research on SEI, we aimed to isolate and
characterize the metabolites of SEI, and to confirm
the principal pathways of SEI metabolism in vivo.
In this study, four main metabolites were isolated from
bile samples after gavage feeding of 100 mg/kg of SEI to
rats. Their structures were identified precisely on the
basis of nuclear magnetic resonance (NMR) and UPLC/
Q-TOF-MS spectra. We also established the main
metabolic pathways of SEI in rats.
Methods
Chemicals and reagents
SEI (purity >99.1%, as tested by HPLC-UV) was obtained
from L. chuanxiong extracts in our laboratory. Its struc-
ture was confirmed by comparison of its MS and NMR
profiles with that published in the literature [24, 25]. Slices
of L. chuanxiong (No. 20130419) were purchased from
Bozhou Medicinal Materials Company (Anhui Province,
China) and authenticated by Professor Zhi-li Zhao of the
Shanghai University of Traditional Chinese Medicine
(Shanghai, China). The ultrahigh purified water used in
this study was prepared in a Milli-Q water purification
system (Millipore Corp., Billerica, MA, USA). Methanol
and acetonitrile (HPLC grade) were purchased from
Merck KGaA (Darmstadt, Germany). MeOH-d4, with
tetramethylsilane (TMS) as internal standard for NMR
analysis, was purchased from Cambridge Isotope Labora-
tories, Inc. (Andover, MS, USA). MCI Gel CHP 20P
(75 μm–150 μm) for column chromatography was
purchased from Mitsubishi (Tokyo, Japan). Sephadex
LH-20 was obtained from GE Healthcare Bio-Sciences
AB (Sweden). Other reagents and chemicals, including
formic acid, were of analytical grade.
Animals and drug administration
Twenty-eight male Sprague–Dawley rats (275–300 g
body weight) were provided by the Experimental Animal
Centre, Shanghai University of Traditional Chinese
Medicine, China. Animals were housed at an ambient
temperature of 24 ± 2 °C and 60 ± 5% humidity, with a
12 h dark–light cycle. They were kept in an environmen-
tally controlled breeding room and given tap water and
fed ad libitum until 12 h before the experiment. Animal
experimental procedures and welfare were strictly in
accordance with the Guide for the Care and Use of
Laboratory Animals and the related ethics regulations
of Shanghai University of TCM. Our animal protocol
was approved by the Institutional Animal Care and
Use Committee, Shanghai University of TCM (Shanghai,
China). SEI was dissolved in deionized water (10 mg•ml-1)
Fig. 1 Chemical structures of the SEI and its metabolites M1–M4
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and administered by gavage at a dose of 100 mg•kg-1 body
weight.
Samples collection and processing procedures
The 28 rats were intraperitoneally injected with urethane
(1.0 g · kg−1 body weight). Under anesthesia, a polyethylene
cannula was inserted into the bile duct. Bile samples were
collected for 12 h (approximately 400 mL in total) after
oral administration of SEI at a dose of 100 mg · kg−1 body
weight. Blank rat bile was collected before oral administra-
tion. All the samples were stored at −20 °C until further
isolation and analysis.
Bile samples (100 μL) for HPLC-UV analysis were
mixed with 400 μL of methanol for 60 s. They were then
centrifuged at 13,000 rpm for 10 min, the supernatant
was next transferred to a clear Eppendorf tube and then
used 20 μLwas analysed using a HPLC-UV system.
Isolation and purification of the metabolites of bile
samples
About 400 ml of bile samples, which were centrifuged
at 5,000 rpm for 10 min at 4 °C firstly, were sub-
jected to MCI Gel CHP 20P column chromatography
(Φ 4.5 × 70 cm) and eluted with a MeOH-H2O step-
wise gradient (0:100, 10:90; 20:80, 30:70, 45:55, 60:40, v/v).
The metabolites were mainly obtained from the 10%, 20%
and 30% MeOH-H2O fractions. The fractions were
concentrated in vacuo to yield residues. The residues were
dissolved in a small amount of 30% MeOH-H2O,
subjected to a Sephadex LH-20 column (Φ 2.5 × 150 cm)
and eluted with 30% MeOH-H2O. The metabolites were
further purified by preparative HPLC, performed with an
Agilent Zorbax Eclipse XDB-C18 (5 μm, 9.4 × 250 mm) at
30 °C in an Agilent 1200 HPLC system (Agilent Technolo-
gies, USA). The detection wavelength was set at 278 nm.
The mobile phase component A was water and B was
acetonitrile, at a flow rate of 3 ml.min−1, and the
column was eluted with a linear gradient of 4–15% B
over 0–15 min, 15–20% B over 15–42 min, 20–60% B
over 42–44 min and finally, the column was recondi-
tioned with 4% B for 4 min to give M1 (57 mg), M2
(68 mg), M3 (14 mg) and M4 (61 mg).
HPLC-UV analysis conditions
Analytical HPLC-UV analysis was carried out on an Agi-
lent 1200 Series analytical HPLC system (Agilent Tech-
nologies, USA). A 20-μL injection loop and a Grace C18
reversed-phase column (5 μm, 4.6 × 150 mm), protected
by an Security Guard Cartridges C18 (5 μm, 4 × 3.0 mm)
guard column, were used for analysis. The analytic HPLC
conditions comprised: a flow rate of 1 mL•min-1; the
mobile phase component A was water with 0.1% formic
acid and B was acetonitrile; the column was eluted with a
linear gradient of 4% B over 0–2 min, 4–8% B over
2–5 min, 8–28% B over 5–41 min, 28–4% B over 41–
43 min and the composition was maintained 4% B for
2 min. The detector wavelength was set at 278 nm and
column temperature was maintained at 25 °C.
Chromatographic and mass spectrometric conditions
Chromatography was performed on an ACQUITY™
UPLC system (Waters Corp., Milford, MA, USA) with a
conditioned auto sampler at 10 °C. The chromatographic
separation was carried out on an ACQUITY UPLC HSS
T3 column (1.8 μm, i.d. 2.1 × 100 mm). The column
temperature was maintained at 45 °C. The analysis was
achieved with gradient elution using A (aqueous 0.1%
formic acid) and B (acetonitrile) as the mobile phase.
The gradient condition of the metabolites analysis was
0–15 min 20% B. The injection volume was 5 μL. The
electrospray ionization source was operated in positive
ionization mode with the capillary voltage at 2.7 kV. The
source and desolvation temperatures were set to 120 °C
and 400 °C, respectively. The cone gas flow was 50 L.h−1
and the desolvation gas was set to 700 L/h.
NMR spectroscopy
A Broker AV 600 NMR spectrometer (Faellanden,
Switzerland) was used to record 1H NMR (600 MHz)
and 13C NMR (125 MHz) spectra in C5D5N at 25 °C.
Chemical shifts were expressed in parts per million
(ppm), with tetramethylsilane as the standard.
Results
Isolation and identification of SEI metabolites
As shown in Fig. 2, four main metabolites were found in
bile samples of rats after oral administration of SEI, none
of which had been isolated previously. The chemical
structures of the metabolites were elucidated on the
basis of UPLC/Q-TOF-MS and NMR spectra (1H NMR,
13C NMR), heteronuclear single quantum coherence
(HSQC) and the heteronuclear multiple-bond correlation
(HMBC).
Careful analysis of the data collected from the UPLC/
Q-TOF-MS system resulted in the identification of four
metabolites in rat bile (M1-M4). Their [M +H]+ ions
were at m/z 401.1455, 401.1453, 514.1870 and 514.1874
for M1-M4, respectively (Fig. 3). The elemental
compositions, experimental mass, calculated mass,
double-bond equivalents (DBE) and the mass errors
of the [M +H]+ ions are shown in Table 1. The λ
max values observed in the UV spectra of these four
metabolites were 274 (M1), 275 (M2), 278 (M3) and
277 (M4) nm, suggesting that the metabolites have
similar chromophore frameworks to SEI. The struc-
tures of theses metabolites were further elucidated by
NMR spectroscopy. Metabolites M1 and M2 were
glucuronide conjugates, and the linkage positions
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were at the 6- or 7-hydroxyl positions. For the gluta-
thione conjugates metabolites M3 and M4, the
linkage positions were at the 7-hydroxyl position, but
they are cis-trans isomers of each other.
Metabolites M1 and M2
Metabolites M1 and M2 showed retention times of 4.18
and 4.70 min on the UPLC system (Fig. 4), with the
same protonated molecular ion at m/z 401. Q-TOF-MS
Fig. 2 Chromatograms for the analysis of the four metabolites of SEI in rat bile. (A) HPLC-UV chromatograms of control bile; (B) HPLC-UV
chromatograms of M1-M4 and SEI standards without bile; (C) Bile samples from rats after oral administration 100 mg/ml of SEI
Fig. 3 MS spectra of M1-M4
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showed the protonated molecular ion at m/z 401.1455
(calculated 401.1448) for M1 and 401.1453 (calculated
401.1448) for M2, corresponding to the same molecular
formula, C18H25O10. The molecular formulas of the
two metabolites were further supported by the NMR
spectral data.
The 13C NMR data of M1 (Table 2) clearly showed the
existence of a glucuronic acid unit [δC 104.2 (C-1′), 74.8
(C-2′), 77.9 (C-3′), 73.6 (C-4′), 76.4 (C-5′) and 176.8
(C-6′)] [26]. It also showed signals from the butylidene
side chain in the 13C NMR data [δC 114.4 (C-8), 29.0
(C-9), 23.3 (C-10) and 14.1 (C-11)] in the aglucon
part of M1. The 13C NMR spectra [δC 170.8 (C-1),
150 (C-3), 156.0 (C-3a) and 126.4 (C-7a)] certified a
five membered lactone ring. Two oxygen-bearing carbon
signals were observed at δC 79.5 (C-6) and 63.5 (C-7),
which were both tertiary carbons and the vicinal hydroxy-
methine protons appeared at δH 4.07 (m) and 4.46
(d, J = 3.3 Hz). All the NMR spectra of M1 were
similar to those of SEI [24, 25], except for the add-
itional glucuronic acid unit. In our previous study
[23], we noted that glucuronidation was one of the
major metabolic pathways of SEI in vivo, and the
structure this metabolite was elucidated as SEI-6S-O-
β-D-glucuronide or SEI-7S-O-β-D-glucuronide. In the
present study, there was a long-range correlation
between H-6 (δH 4.07, m) and C-1′ (δC 79.5) in
HMBC spectrum (Table 2). Thus, the structure of
M1 was definitively identified as SEI-6S-O-β-D-glucuronide
with the help of 2D-NMR.
The 13C NMR data of M2 (Table 2) also clearly
showed the existence of a glucuronic acid moiety [δC
104.7 (C-1′), 75.1 (C-2′), 77.8 (C-3′), 73.6 (C-4′), 75.8
(C-5′) and 176.8 (C-6′)]. The 13C NMR data of the agly-
cone part of M2 (Table 2) were similar to those of M1
(Table 2), except for the carbon signals of C-6 (δC 70.2)
and C-7 (δC 74.9), which were different from those of
M1. Based on the cross peak between C-1′ (δC 104.7)
and H-7 (δH 4.44, d, J = 3.9 Hz) in the HMBC spectrum,
the structure of M2 was elucidated as SEI-7S-O-β-D-
glucuronide.
Metabolites M3 and M4
Metabolites M3 and M4 showed retention times of 4.94
and 5.77 min on the UPLC system (Fig. 4), with the
same protonated molecular ion at m/z 514. Q-TOF-MS
showed the protonated molecular ion at m/z 514.1870
(calculated 514.1859) for M3 and 514.1874 (calculated
514.1859) for M4, corresponding to the same molecular
Table 1 The mass data for metabolites of Senkyunolide I (SEI)
Compound Observed mass (Da) Calculated mass (Da) Error (mDa) Error (ppm) DBE Norm Formula
M1 401.1455 401.1448 0.6 1.5 6.5 0.048 C18H25O10
M2 401.1453 401.1448 0.7 1.7 6.5 0.004 C18H25O10
M3 514.1870 514.1859 1.4 2.7 8.5 2.062 C22H32N3O9S
M4 514.1874 514.1859 1.5 2.9 8.5 1.554 C22H32N3O9S
Fig. 4 Representative UPLC/MS chromatograms of M1-M4
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formula, C22H32N3O9S. The molecular formulae of the
two metabolites were further supported by the NMR
spectral data.
The assignments of all the proton and carbon signals
for M3 and M4 were achieved by 1D and 2D NMR
experiments, and the data are listed in Table 3. The
13C NMR data of M3 clearly showed a glutathione
unit [δC 174.2 (C-1′), 55.8 (C-2′), 33.3 (C-3′), 27.8
(C-4′), 175.6 (C-5′), 55 (C-6′), 172.3 (C-7′), 44.6 (C-8′),
176.1 (C-9′) and 36.7 (C-10′)] [27]. The NMR data of the
other C atoms suggested that M3 has the same parent
construction as M1 and M2. In our previous study [23],
we also observed that glutathione conjugation was one of
the metabolic pathways of SEI in vivo. The HMBC spectra
showed cross peaks between C-10′ (δC36.7) and H-7
(δH 3.86, d, J = 3.3 Hz). Thus, M3 was characterized
as SEI-7S-S-glutathione.
The 1H NMR and 13C NMR data of M4 were similar
to those of M3, and the same planar structure as that of
M3 was deduced from the HSQC and HMBC data of
M4, which suggested that M4 is a diastereoisomer of
M3. In the 1H NMR, the H-7 of M4 (δH 3.59, s) was a
single peak, different from H-7 (δH 3.86, d, J = 3.6 Hz) in
M3, which suggested that M4 is in the 6, 7-cis-
configuration [28]. Thus, the configurations of the 7-
substituted groups were inverted during the metabolic
process, and M4 was identified as SEI-7R-S-glutathione.
Discussion
In our previous study [18], SEI was rapidly absorbed and
exhibited extensive distribution after oral administration.
Its oral bioavailability was approximately 37.25%, but it
was quickly eliminated from plasma, with a half life of
less than 60 min. In a second metabolic experiment [23],
the biotransformation of SEI was investigated using
UPLC/Q-TOF-MS. Eighteen metabolites were identified
and the result indicated that methylation, hydration,
epoxidation, glucuronidation and glutathione conjuga-
tion were the major pathways of SEI metabolism in
vivo. Based on the results above, the fast elimination
from plasma could be explained by rapid and exten-
sive metabolism. However, the chemical structures of
SEI conjugates present in vivo have not been fully
characterized.
In the present study, for the four main metabolites in
bile samples, an elementary conclusion could be gained
by analyzing the height and area of the peaks in HPLC-
UV chromatograms. It suggested that SEI-6S-O-β-D-
glucuronide (M1), SEI-7S-O-β-D-glucuronide (M2), SEI-
7S-S-glutathione (M3) and SEI-7R-S-glutathione (M4)
Table 2 1D and 2D nuclear magenetic resonance (NMR) data of metabolites M1 and M2. (δ in ppm, MeOH-d4)
Position M1 M2
δC δH HMBC δC δH HMBC
1 170.8 - - 171.0 - -
3 150.0 - - 150.0 - -
3a 156.0 - - 156.1 - -
4 18.7 2.48 (1H, ddd, J = 18.7, 5.6, 3.4 Hz) C-5, 6, 7a 18.8 2.53 (2H, m) C-3a, 5, 6, 7a
2.67 (1H, ddd, J = 18.2, 9.5, 5.8 Hz) C-3a, 5, 6, 7a
5 24.3 2.01 (1H, m) C-3a, 4 26.2 1.90 (1H, m) C-3a, 4, 6, 7
2.18 (1H, ddd, J = 14.0, 8.9, 5.4 Hz) C-3a, 4, 6, 7 2.01 (1H, dt, J = 13.7, 5.7 Hz) C-3a, 4, 6, 7
6 79.5 4.07 (1H, m) C-4, 7, 7a, 1′ 70.2 4.13 (1H, m) C-4, 5, 7, 7a
7 63.5 4.46 (1H, d, J = 3.3 Hz) C-1, 3a, 5, 6, 7a 74.9 4.44 (1H, d, J = 3.9 Hz) C-1, 3a, 5, 6, 7a, 1′
7a 126.4 - - 125.3 - -
8 114.4 5.45 (1H, t, J = 7.9 Hz) C-3, 3a, 9, 10 115.2 5.48 (1H, t, J = 7.9 Hz) C-3, 3a, 10
9 29.0 2.34 (2H, dd, J = 15.0, 7.6 Hz) C-3, 8, 10, 11 29.1 2.34 (2H, dd, J = 15.0, 7.5 Hz) C-3, 8, 10, 11
10 23.3 1.51 (2H, m) C-8, 9, 11 23.3 1.52 (2H, dt, J = 14.7, 7.3 Hz) C-8, 9, 11
11 14.1 0.96 (3H, t, J = 7.4 Hz) C-9, 10 14.1 0.95 (3H, t, J = 7.4 Hz) C-9, 10
1′ 104.2 4.46 (1H, d, J = 7.8 Hz) C-3′, 5′ 104.7 4.68 (1H, d, J = 7.8 Hz) C-7
2′ 74.8 3.14 (1H, t, J = 8.3 Hz) C-1′, 3′ 75.1 3.20 (1H, t, J = 8.4 Hz) C-1′, 3′
3′ 77.9 3.38 (1H, t, J = 8.9 Hz) C-2′, 4′ 77.8 3.42 (1H, t, J = 6.0 Hz) C-4′
4′ 73.6 3.41 (1H, t, J = 9.1 Hz) C-3′, 6′ 73.6 3.44 (1H, t, J = 5.8 Hz) C-3′, 6′
5′ 76.4 3.57 (1H, d, J = 9.4 Hz) C-1′, 3′, 4′, 6′ 75.8 3.63 (1H, m) C-1′, 3′, 4′, 6′
6′ 176.8 - - 176.8 - -
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were the major metabolites in vivo. In our experiment,
only trace metabolites of SEI were determined in the
urine of rats, all of which suggested that the final
excretion pathway in rats was bile. The metabolic
pathways of SEI in rat bile mainly involved glucuroni-
dation and glutathione conjugation during the phase
II biotransformation pathway in rats because of the 6- and
7-hydroxyl groups in its structure, and the configurations
of 7-substituted groups may be inverted during glutathi-
one conjugation. Based on the structures of these metabo-
lites, the proposed metabolic pathways of SEI are shown
in Fig. 5.
Glutathione plays an important role in maintaining the
redox state of cells via scavenging reactive oxygen
species. Glutathione conjugation of xenobiotics is a
detoxification pathway that inactivates electrophiles,
which may covalently bind to endogenous proteins,
resulting in potential detrimental effects [29]. This
metabolic mechanism of SEI is indicated for its toxicity,
and further work is needed to clarify the potential toxicity
of SEI. In theory, medicines or metabolites are supposed
to be excreted ultimately out of the body via faeces after
bile excretion. However, we did not detect any metabo-
lites, except for SEI, in fecal samples. Therefore, we
suspect that the toxicity might be derived from its metab-
olites to a great extent. There are a few examples where
phase II metabolism will produce significantly more
biologically active or more toxic metabolites, including
morphine [30] and certain heterocyclic aromatic amine
compounds [31, 32]. In this study, we identified only four
main metabolites of SEI in vivo and further research will
be carried out to identify other metabolites. Issues to be
addressed comprise structure–activity relationship
analysis, bioactivity evaluation, and the quantitative
mass balance of these metabolites.
Conclusions
Our results demonstrated that glucuronide and glutathione
conjugation are the major pathways of SEI metabolism in
Table 3 1D and 2D nuclear magenetic resonance (NMR) data of metabolites M3 and M4. (δ in ppm, MeOH-d4)
Position M3 M4
δC δH HMBC δC δH HMBC
1 169.9 - - 170.8 - -
3 149.7 - - 150.0 - -
3a 152.9 - - 153.4 - -
4 21.2 2.46 (1H, m) C-3a, 5, 6, 7a 17.4 2.46 (1H, m) C-3a, 5, 6, 7a
2.57 (1H, m) C- 3a, 6, 7a 2.50 (1H, m) C-3a, 5, 7a
5 26.9 1.94 (2H, m) C-3a, 4, 6, 7 24.6 1.95 (2H, m) C- 3a, 4, 6, 7
6 70.3 4.08 (1H, dt, J = 11.2, 3.6 Hz) C-4, 5, 7 70.0 4.17 (1H, m) C-4, 7a
7 45.4 3.86 (1H, d, J = 3.8 Hz) C-1, 3a, 5, 6, 7a, 10′ 43.1 3.59 (1H, s) C-1, 3a, 5, 6, 7a, 10′
7a 127.3 - - 125.7 - -
8 114.5 5.37 (1H, t, J = 7.9 Hz) C-3, 3a, 10 114.2 5.40 (1H, t, J = 7.9 Hz) C-3, 3a, 10
9 29.1 2.29 (2H, dd, J = 15.0, 7.6 Hz) C-3, 8, 10, 11 29.0 2.31 (2H, dd, J = 15.0, 7.5 Hz) C-3, 8, 10, 11
10 23.3 1.48 (2H, dd, J = 14.7, 7.4 Hz) C-8, 9, 11 23.3 1.48 (2H, m) C-8, 9, 11
11 14.1 0.93 (3H, m) C-9, 10 14.1 0.93 (3H, t, J = 7.4 Hz) C-9, 10
1′ 174.2 - - 174.5 - -
2′ 55.8 3.63 (1H, m) C-1′, 3′, 5′ 55.7 3.63 (1H, t, J = 6 Hz) C-1′, 3′, 5′
3′ 33.3 2.60 (2H, m) C-2′, 4′, 5′ 33.2 2.54 (2H, m) C-2′, 4′, 5′
4′ 27.8 2.15 (2H, dt, J = 14.3, 7.3 Hz) C-2′, 3′, 5′ 28.0 2.13 (2H, m) C-2′, 3′, 5′
5′ 175.6 - - 175.4 - -
6′ 55.0 4.67 (1H, m) C-5′, 7′, 10′ 55.0 4.66 (1, m) C-5′, 7′, 10′
7′ 172.3 - - 172.2 - -
8′ 44.6 3.72 (2H, s) C-7′, 9′ 44.7 3.69 (1H, d, J = 17.1 Hz) C-7′, 9′
3.77 (1H, d, J = 17.1 Hz) C-7′, 9′
9′ 176.1 - - 176.4 - -
10′ 36.7 3.12 (1H, dd, J = 14.2, 7.7 Hz) C-7, 6′, 7′ 35.7 3.00 (1H, dd, J = 13.9, 8.4 Hz) C-7, 6′, 7′
3.22 (1H, dd, J = 14.1, 5.0 Hz) C-7, 6′, 7′ 3.22 (1H, dd, J = 13.9, 5.3 Hz) C-7, 7′
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vivo, and the configuration at the 7th-position could be
inverted during glutathione conjugation.
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